Open AccessRationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)
Author(s) -
Masahiro Iwasaku,
Junichi Uchino,
Tadaaki Yamada,
Yusuke Chihara,
Takayuki Shimamoto,
Nanako Tamiya,
Yoshiko Kaneko,
Fumiaki Kiyomi,
K. Takayama
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.08.03
Subject(s) - medicine , epidermal growth factor receptor , adverse effect , clinical endpoint , gefitinib , discontinuation , egfr inhibitors , oncology , lung cancer , dermatology , pharmacology , clinical trial , cancer
Dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to significantly improve overall survival in the patients of EGFR mutation-positive inoperable or postoperative recurrent non-small cell lung cancer (NSCLC). However, dermatologic adverse events (AEs) increase with dacomitinib treatment, and the management strategy for dermatologic AEs is crucial. In particular, a proactive strategy has become desirable in clinical practice settings. We designed a trial to assess a proactive strategy for dermatologic AEs associated with dacomitinib treatment.